ENVVENO MEDICAL CORP
NVNONASDAQTrading Snapshot
- Day Range
- $908.92 – $920.32
- 52-Week Range
- $7.01 – $35.53
- Volume
- $3.28B
- Avg Volume
- $3.09B
- Shares Outstanding
- 16,503
- Next Earnings
- Oct 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $15,583
- Last Q Revenue
- $4,074
- P/E Ratio
- -0.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-23.43
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −1.1%
Why Investors Own NVNO
- ✓High-growth profile — revenue up +22.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 30% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ENVVENO MEDICAL CORP
NVNO
StockOtter · stockotter.spaceAbout ENVVENO MEDICAL CORP
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
ENVVENO MEDICAL CORP tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift NVNO price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
ENVVENO MEDICAL CORP announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.